Overall, the BAdV-(H5N1)HA+ (H7N9)NP vaccine elicited AIV-specific humoral, mucosal, and cellular immune responses and was associated with a reduced percentage of virus-isolation-positive tracheal samples, particularly following IO administration, compared with the other vaccination routes.
Abstract
Avian influenza virus (AIV) remains a persistent threat to global poultry health and production, necessitating the development of novel and effective vaccination strategies. This study evaluated the immunogenicity and protective efficacy of a newly developed bovine adenovirus-vector-based avian influenza virus (BAdV-AIV) vaccine expressing the hemagglutinin (HA) gene of H5N1 and the nucleoprotein (NP) gene of H7N9 AIV subtypes (BAdV - (H5N1)HA+(H7N9)NP). In our study, the candidate vaccine was administered via three mucosal routes: oral (OR), intranasal (IN), or intraocular (IO), using three different doses (10⁶, 10⁷, and 10⁸ pfu/bird) in a prime-boost vaccination regimen in broiler chickens. Immunological analyses revealed that high-dose vaccination, administered via the IO route induced a substantial upregulation of virus-specific systemic IgY, hemagglutination inhibition (HI) antibody titers, mucosal sIgA antibody responses in bile, trachea and intestines, and activation of various T-cell subsets (helper T cells, cytotoxic T cells, and γδ T lymphocytes). The quantitative PCR (qPCR) assay failed to detect a difference in the challenge H5N2 AIV genomic equivalent load in the vaccinated groups. A qualitative analysis for live challenge virus detection was performed by inoculating the tracheal swab fluid into embryonated chicken eggs and harvested allantoic fluid was tested by hemagglutination assay. Our data showed a lower percentage of tracheal samples yielding detectable live virus in the high-dose BAdV-(H5N1)HA+H7N9)NP AIV vaccine group, particularly following IO administration, compared with the other vaccination routes. Overall, the BAdV-(H5N1)HA+ (H7N9)NP vaccine elicited AIV-specific humoral, mucosal, and cellular immune responses and was associated with a reduced percentage of virus-isolation-positive tracheal samples, particularly following IO administration. These findings support the need for further evaluation of this vaccine platform for avian influenza control in poultry.
The results demonstrate safety and immunogenicity of bat influenza vectored H5 vaccine candidates and indicate that polymerase compatibility with the avian host can enhance the vaccine immunogenicity.
The avian influenza virus (AIV) poses a serious threat to the poultry industry, leading to substantial economic losses and having the potential to cause severe zoonotic diseases worldwide. The development of mucosal vaccines has prompted greater attention due to their ability to mimic the natural infection process and...
R. S. Kurnia, C. M. Nugroho, O. M. Silaen et al.· Avian Pathology· 0 citations
The H5N8 vaccine with the IB160 adjuvant was well tolerated locally and systemically, without compromising vital organ function and consistent with expectations for adjuvanted influenza vaccines, demonstrating strong and durable humoral and cellular immune responses.
D. Maria, Isabela Mancini Martins, Giselle Pidde Marques Porto et al.· Vaccine· 0 citations
A chimeric subunit vaccine, RBD-HA, in which the receptor-binding domain of the QX-type IBV spike protein replaced the immunodominant head domain of H9N2 AIV haemagglutinin is developed, providing proof of concept for a bivalent subunit vaccine targeting two major avian respiratory viruses.
Background Avian influenza viruses (AIVs), particularly highly pathogenic H5 and H7 viruses, pose major threats to poultry production, food security, international trade, and public health. Vaccination is an important component of AIV control; however, antigenic evolution, incomplete reduction of viral shedding, and ch...
M. Nazari, M. Mehrazar· Veterinary and Animal Scienc...· 0 citations
Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.
Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.